High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.
Renke
Marcin
M
Tylicki
Leszek
L
Knap
Narcyz
N
Rutkowski
Przemyslaw
P
Neuwelt
Alexander
A
Petranyuk
Andriy
A
Larczynski
Wojciech
W
Wozniak
Michał
M
Rutkowski
Boleslaw
B
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D001565:Benzoates / Q000008:administration & dosage; D017315:Cilazapril / Q000008:administration & dosage; D018592:Cross-Over Studies; D015237:Dinoprost / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D028421:Isoprostanes / Q000652:urine; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D028421:Isoprostanes; D017315:Cilazapril; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D000077333:Telmisartan